ORGANON GETS FIRST EUROPEAN MARKETING APPROVAL FOR REMERON.CIMA LABS INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . (Nasdaq:CIMA), Eden Prairie, Minn., has announced that its pharmaceutical partner, Organon or·ga·non or or·ga·num n. pl. or·ga·nons or or·ga·nums or or·ga·na 1. An organ. 2. A set of principles for use in scientific investigation. organon pl. organa [Gr.] organ. , has received its first European marketing approval for Remeron(R) SolTab(TM) from the Dutch Medicines Evaluation Board. The Dutch regulatory approval triggers a mutual recognition procedure involving other European countries. Remeron SolTab, an antidepressant antidepressant, any of a wide range of drugs used to treat psychic depression. They are given to elevate mood, counter suicidal thoughts, and increase the effectiveness of psychotherapy. that incorporates CIMA's OraSolv(R) fast-dissolve drug delivery system with Organon's active drug ingredient, mirtazapine, received U.S. regulatory approval in January 2001 and became commercially available in this year's first quarter. Remeron, which has been available in the U.S. since 1996 in solid oral dosage form, has been Organon's best-selling U.S. product. CIMA is Organon's exclusive supplier of Remeron SolTab. In a separate development, the company announced that earlier in July, CIMA was included in the Russell 3000(R) Index, a stock market index composed of the 3,000 largest stocks in the U.S. equity market ranked by market capitalization Market Capitalization A measure of a public company's size. Market capitalization is the total dollar value of all outstanding shares. It's calculated by multiplying the number of shares times the current market price. This term is often referred to as market cap. as of May 31. About CIMA LABS CIMA develops and manufactures prescription and over-the-counter products for pharmaceutical companies based upon its proprietary, fast-dissolve drug delivery technologies, OraSolv(R) and DuraSolv(TM). CIMA formulates a pharmaceutical company's active drug ingredient into a new, orally disintegrating dosage form that dissolves quickly in the mouth without chewing or the need for water. Taste masking agents may be used with the company's fast-dissolve technologies to prevent or minimize the unpleasant taste associated with many active drug ingredients. CIMA currently manufactures five pharmaceutical brands utilizing its OraSolv and DuraSolv technologies: three prescription and two over-the-counter. For more information, call 952/947-8700. >TX CORIXA GET $1 MILLION MILESTONE PAYMENT FROM JAPAN TOBACCO >TX Corixa Corporation (Nasdaq: CRXA), Seattle, a developer of immunotherapeutics, has received a $1 million milestone payment as a result of its research collaboration and license agreement with the pharmaceutical division of Japan Tobacco Inc. (JT) to support Corixa's development of therapeutic lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. vaccines. The milestone was achieved following JT's selection of a Corixa antigen for further development. This is the first milestone payment Corixa has received under the terms of a 1999 agreement with JT, which provides JT with certain rights to develop vaccine products containing Corixa's novel lung cancer antigens, including antigens formulated using Corixa's microsphere Not to be confused with Glass microphere. This article largely refers to micropheres or protein protocells as small spherical units postulated by some scientists as a key stage in the origin of life. delivery system and proprietary adjuvant adjuvant /ad·ju·vant/ (aj?dbobr-vant) (a-joo´vant) 1. assisting or aiding. 2. a substance that aids another, such as an auxiliary remedy. 3. technologies. The agreement provides JT with exclusive rights to vaccine products aimed at treating lung cancer and potentially other solid tumors in humans, principally in Japan and North America, as well as co-exclusive rights with Zambon Group spa in China. Under the agreement, Corixa may receive a total of over $40 million in license fees, research funding and milestone payments based upon successful clinical and commercial progress. "Our achievement of this milestone represents continued advancement of our lung cancer antigen discovery program," said Steven Gillis, Ph.D., chairman and chief executive officer of Corixa. "We are pleased with the progress of our collaboration with JT and hopeful that our discovery efforts will be used in lung cancer therapeutic products worldwide." About Corixa Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , cancer and infectious diseases by understanding and directing the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. Corixa currently has 16 programs in clinical development and 22 programs in preclinical development, including its most advanced product candidate, Bexxar(TM), a monoclonal antibody conjugated conjugated adj. Conjugate. estrogens, conjugated Warning - Hazardous drug! C.E.S. to a radioisotope radioisotope: see radioactive isotope. Radioisotope (biology) A radioactive isotope used in studying living systems, such as in the investigation of metabolic processes. . The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, Washington, with additional operations in Hamilton, Montana and South San Francisco, California South San Francisco is a city in San Mateo County, California, United States, located on the San Francisco Peninsula in the San Francisco Bay Area. The population was 60,552 at the 2000 census. . For more information, visit http://www.corixa.com or call 1.877.4CORIXA or 1.877.426.7492. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion